Segall Bryant & Hamill, LLC Galapagos Nv Transaction History

Segall Bryant & Hamill, LLC

$6.35 Billion
Q1 2025

A detailed history of Segall Bryant & Hamill, LLC transactions in Galapagos Nv stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 651,461 shares of GLPG stock, worth $20.9 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

651,461

Previous 685,867 5.02%

Holding current value

$20.9 Million

Previous $18.9 Million 13.24%

% of portfolio

0.26%

Previous 0.27%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 02, 2025	SELL	$22.69 - $28.79 $780,672 - $990,548	-34,406 Reduced 5.02%	651,461 $16.4 Million
Q4 2024 Feb 11, 2025	SELL	$25.22 - $31.05 $498,876 - $614,200	-19,781 Reduced 2.8%	685,867 $18.9 Million
Q3 2024 Nov 08, 2024	SELL	$24.2 - $30.67 $2.26 Million - $2.87 Million	-93,431 Reduced 11.69%	705,648 $20.3 Million
Q2 2024 Aug 14, 2024	SELL	$24.78 - $32.48 $1.71 Million - $2.24 Million	-68,963 Reduced 7.94%	799,079 $19.8 Million
Q1 2024 May 15, 2024	SELL	$32.2 - $42.44 $215,289 - $283,753	-6,686 Reduced 0.76%	868,042 $28 Million
Q4 2023 Feb 14, 2024	BUY	$31.87 - $40.71 $4.36 Million - $5.57 Million	136,737 Added 18.53%	874,728 $35.6 Million
Q3 2023 Nov 09, 2023	BUY	$34.17 - $42.98 $11.8 Million - $14.9 Million	346,630 Added 88.57%	737,991 $25.5 Million
Q2 2023 Aug 11, 2023	BUY	$37.4 - $44.52 $3.44 Million - $4.09 Million	91,970 Added 30.72%	391,361 $15.9 Million
Q1 2023 May 15, 2023	BUY	$36.5 - $48.0 $10.9 Million - $14.4 Million	299,391 New	299,391 $11.6 Million

Others Institutions Holding GLPG

# of Institutions

Shares Held

13.4M

Call Options Held

216K

Put Options Held

313K

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $2.12B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.

Account

Segall Bryant & Hamill, LLC Galapagos Nv Transaction History